Phase I Trial of the Novel Mammalian Target of Rapamycin...

Phase I Trial of the Novel Mammalian Target of Rapamycin Inhibitor Deforolimus (AP23573; MK-8669) Administered Intravenously Daily for 5 Days Every 2 Weeks to Patients With Advanced Malignancies

Mita, M. M., Mita, A. C., Chu, Q. S., Rowinsky, E. K., Fetterly, G. J., Goldston, M., Patnaik, A., Mathews, L., Ricart, A. D., Mays, T., Knowles, H., Rivera, V. M., Kreisberg, J., Bedrosian, C. L., To
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
26
Language:
english
Journal:
Journal of Clinical Oncology
DOI:
10.1200/JCO.2007.12.0345
Date:
January, 2008
File:
PDF, 400 KB
english, 2008
Conversion to is in progress
Conversion to is failed